AzurRx BioPharma Inc (AZRX) Gets a Buy Rating from H.C. Wainwright

By Ryan Adsit

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma Inc (AZRXResearch Report) today and set a price target of $6. The company’s shares closed last Monday at $0.97, close to its 52-week low of $0.86.

Chen observed:

“Our price target is derived from a market value of the firm at $199M, which includes a discounted cash flow- based asset value of $201M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding $2M convertible debt, with 50% probability of success. Risks include, but are not limited to: (1) failure of MS1819 in clinical trials; (2) failure of MS1819 to secure regulatory approval; (3) failure of MS1819 to achieve commercial success due to reimbursement, penetration rate, and/or competition; and (4) dilution risk.”

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -19.5% and a 26.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.

AzurRx BioPharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $6.67.

See today’s analyst top recommended stocks >>

Based on AzurRx BioPharma Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.66 million. In comparison, last year the company had a GAAP net loss of $3.31 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.